Willow Biosciences Inc. announced that the Board of Directors has appointed Dr. Chris Savile, Willow's Chief Operations Officer, as President and Mr. Trevor Peters, a Director and Founder of the Company, as Chairman, effective March 28, 2023, in connection with Dr. Peter Seufer-Wasserthal's retirement as President. Dr. Seufer-Wasserthal will continue to be a Director of the Company. Dr. Savile, a leader at Willow since the Company's inception in early 2019.

Since joining Willow, Dr. Savile has led the development of the technology platform, building of the operational capabilities, and expansion of the internal portfolio and external partnerships. Prior to joining Willow, Dr. Savile worked in senior leadership roles at Intrexon Corporation, and Codexis Inc. Chris is an experienced business professional and an accomplished chemist, high-throughput assay scientist, and protein engineer with a strong technical background. The Company also announced that Dr. Trish Choudhary, Willow's VP Research and Development, has been promoted to the role of Sr. VP Research and Development. Dr. Choudhary has been with the Company since its inception in 2019, leading the Company's R&D program in Mountain View, California.

Dr. Choudhary has built and continues to build Willow's genetic engineering technology that includes enzyme engineering, strain engineering and its recently-developed genome-wide high-throughput editing technology. These tools have enabled the rapid development and commercialization of the company's first precision fermentation product, cannabigerol (CBG), development of the aforementioned biooxidation manufacturing platform, and development of alternative hosts to broaden the company's capabilities and offering. Additionally, Mr. Raffi Asadorian will join the Board of Directors as an independent director following the Company's upcoming annual general meeting of shareholders on May 12, 2023 (the AGM).

Mr. Asadorian has been the Chief Financial Officer of AcelRx Pharmaceuticals, since August 2017. Mr. Asadorian has over 30 years of experience in finance, including 15 years' experience as a CFO with publicly listed and private equity-owned biotech and life sciences companies including Amyris and Barr Pharmaceuticals . Prior to that, Mr. Asadorian was a Partner in the Transaction Services Group of PwC, LLP in New York.

Mr. Asadorian holds an MBA in Finance from the University of Manchester and a B. Sc., Business Administration in Accounting from Xavier University in Cincinnati. Mr. Asadorian is a Certified Public Accountant (inactive, Ohio). Mr. Trevor Peters, a Director and Founder of the Company, will succeed Dr. Peter Seufer-Wasserthal as Chairman of the Board.

Ms. Barbara Munroe will continue to serve as a Director and Chair of the Governance and Compensation Committee but will no longer serve as Lead Independent Director. Mr. Sadiq Lalani will not stand for re-election as a director at the Company's upcoming AGM due to other commitments.